OTCMKTS:ASCLF Ascletis Pharma (ASCLF) Stock Price, News & Analysis → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free ASCLF Stock Alerts $0.20 0.00 (0.00%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$0.20▼$0.2050-Day Range$0.20▼$0.2052-Week Range$0.15▼$0.40VolumeN/AAverage Volume4,243 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Ascletis Pharma alerts: Email Address Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Ascletis Pharma Stock (OTCMKTS:ASCLF)Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB); ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.Read More ASCLF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASCLF Stock News HeadlinesApril 3, 2024 | prnewswire.comAscletis Announces Strategic Decisions on FXR agonist ASC42March 10, 2024 | prnewswire.comAscletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual MeetingMay 1, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”January 28, 2024 | seekingalpha.comWeek In Review: Arrivent BioPharma Raises $175M In IPO For In-Licensings From ChinaJanuary 24, 2024 | finance.yahoo.comAscletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of AcneJanuary 23, 2024 | finance.yahoo.comGannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASHJanuary 2, 2024 | finance.yahoo.comGannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic SteatohepatitisDecember 5, 2023 | finance.yahoo.comAscletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of AcneMay 1, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”November 12, 2023 | finance.yahoo.comAscletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHBNovember 8, 2023 | finance.yahoo.comDr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023November 6, 2023 | finance.yahoo.comGannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&DSeptember 28, 2023 | finance.yahoo.comAscletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional CureSeptember 26, 2023 | msn.comAscletis enrols all patients in trial of glioblastoma therapySeptember 26, 2023 | finance.yahoo.comAscletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent GlioblastomaJuly 24, 2023 | prnewswire.comClinical Results of ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection Presented at the 12th IAS Conference on HIV ScienceJune 26, 2023 | finance.yahoo.comAscletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023May 8, 2023 | markets.businessinsider.comAscletis Pharma: China Approves To Conduct Phase IIa Clinical Trial For ASC10 To Treat RSV InfectionMay 8, 2023 | finance.yahoo.comAscletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus InfectionMay 2, 2023 | finance.yahoo.comAscletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for AcneFebruary 27, 2023 | finance.yahoo.comAscletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech IndexJanuary 31, 2023 | finance.yahoo.comAscletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus InfectionJanuary 26, 2023 | finance.yahoo.comAscletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China NMPAJanuary 17, 2023 | msn.comSupply enters ritonavir tablets supply agreement with SimcereJanuary 16, 2023 | finance.yahoo.comAscletis Announces Entering into a Supply Agreement of Ritonavir Tablets with SimcereJanuary 15, 2023 | finance.yahoo.comAscletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19January 3, 2023 | msn.comViking Therapeutics sues Ascletis Pharma for stealing trade secretsSee More Headlines Receive ASCLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascletis Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:ASCLF CUSIPN/A CIKN/A Webwww.ascletis.com Phone86-571-8538-9730FaxN/AEmployees219Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Jinzi Jason Wu Ph.D. (Age 60)Founder, Chairman & CEO Comp: $3.12MMs. Hejingdao Wu (Age 49)Senior VP of Operations & Executive Director Comp: $368.04kMs. Yuemei Yan (Age 54)Senior Vice President of Clinical Development Operations Dr. Kristjan Sigurdur Gudmundsson (Age 56)Senior Consultant & Head of Discovery Dr. George Zhengzhi Hill (Age 73)Senior Consultant & Chief Medical Advisor Mr. John P. Gargiulo M.B.A.Chief Business OfficerMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors ASCLF Stock Analysis - Frequently Asked Questions How have ASCLF shares performed in 2024? Ascletis Pharma's stock was trading at $0.1682 at the beginning of the year. Since then, ASCLF shares have increased by 20.3% and is now trading at $0.2023. View the best growth stocks for 2024 here. How do I buy shares of Ascletis Pharma? Shares of ASCLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ASCLF) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority Gold😱 This phenomenon is smashing regular market gainsMillPubElon’s New Device is About to Shock the WorldInvestorPlaceYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascletis Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
